Biomarin Stock Analysis

BMRN
 Stock
  

USD 97.12  5.90  5.73%   

The latest bullish price patterns experienced by current Biomarin Pharmaceutical shareholders could raise concerns from institutional investors as the firm is trading at a share price of 97.12 on 1,303,693 in volume. The company directors and management have been very successful in rebalancing the firm assets at opportune times to take advantage of market volatility in November. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.19. The current volatility is consistent with the ongoing market swings in November 2022 as well as with Biomarin Pharmaceutical unsystematic, company-specific events.
Continue to Trending Equities.
  
The Biomarin Pharmaceutical stock analysis report makes it easy to digest most publicly released information about Biomarin Pharmaceutical and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biomarin Stock analysis module also helps to analyze the Biomarin Pharmaceutical price relationship with some important fundamental indicators such as market cap and management efficiency.

Biomarin Stock Analysis Notes

About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Biomarin Pharmaceutical was currently reported as 24.59. The company has Price/Earnings To Growth (PEG) ratio of 0.58. Biomarin Pharmaceutical had not issued any dividends in recent years. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company was incorporated in 1996 and is headquartered in San Rafael, California. Biomarin Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3045 people. For more info on Biomarin Pharmaceutical please contact JeanJacques Bienaime at 415 506 6700 or go to https://www.biomarin.com.

Biomarin Pharmaceutical Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biomarin Pharmaceutical's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biomarin Pharmaceutical or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
The company reported the previous year's revenue of 1.85 B. Net Loss for the year was (64.08 M) with profit before overhead, payroll, taxes, and interest of 1.38 B.
Over 99.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: BioMarin Pharmaceutical Stock Increases Over 7 percent Details - Pulse 2.0

Biomarin Pharmaceutical Upcoming and Recent Events

Earnings reports are used by Biomarin Pharmaceutical to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biomarin Pharmaceutical previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Biomarin Pharmaceutical SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biomarin Pharmaceutical prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biomarin Pharmaceutical investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biomarin Pharmaceutical specific information freely available to individual and institutional investors to make a timely investment decision.
12th of September 2022
Regulation FD Disclosure
View
3rd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
31st of May 2022
Submission of Matters to a Vote of Security Holders
View
5th of May 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
27th of April 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
11th of March 2022
Unclassified Corporate Event
View
23rd of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
14th of February 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Unclassified Corporate Event. Entry into a Material Definitive Agreement
View

Biomarin Pharmaceutical Thematic Classifications

In addition to having Biomarin Pharmaceutical stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech
Biotechnology and pharmaceuticals production and services

Biomarin Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 18.77 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biomarin Pharmaceutical's market, we take the total number of its shares issued and multiply it by Biomarin Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Biomarin Profitablity

Biomarin Pharmaceutical's profitability indicators refer to fundamental financial ratios that showcase Biomarin Pharmaceutical's ability to generate income relative to its revenue or operating costs. If, let's say, Biomarin Pharmaceutical is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biomarin Pharmaceutical's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biomarin Pharmaceutical's profitability requires more research than a typical breakdown of Biomarin Pharmaceutical's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.04 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average.
Last ReportedProjected for 2022
Return on Investment(1.56) (1.69) 
Return on Average Assets(1.08) (1.17) 
Return on Average Equity(1.53) (1.65) 
Return on Invested Capital(0.011) (0.0118) 
Return on Sales(0.033) (0.0356) 

Management Efficiency

The value of Return on Investment is estimated to slide to -1.69. The value of Return on Average Assets is estimated to slide to -1.17. Biomarin Pharmaceutical Total Assets are quite stable at the moment as compared to the past year. The company's current value of Total Assets is estimated at 6.48 Billion. Goodwill and Intangible Assets is expected to rise to about 611.1 M this year, although the value of Current Assets will most likely fall to about 1.8 B. Biomarin Pharmaceutical management efficiency ratios could be used to measure how well biomarin pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for 2022
Book Value per Share 23.36  20.90 
Enterprise Value over EBIT(278.00) (285.32) 
Enterprise Value over EBITDA 347.34  374.76 
Price to Book Value 3.80  4.40 
Tangible Assets Book Value per Share 29.63  26.82 
Enterprise Value16.7 B16.5 B
Tangible Asset Value5.4 B4.7 B

Technical Drivers

As of the 2nd of December, Biomarin Pharmaceutical shows the Downside Deviation of 2.14, mean deviation of 1.61, and Risk Adjusted Performance of 0.1604. Biomarin Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Biomarin Pharmaceutical, which can be compared to its rivals. Please confirm Biomarin Pharmaceutical coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Biomarin Pharmaceutical is priced correctly, providing market reflects its regular price of 97.12 per share. Given that Biomarin Pharmaceutical has jensen alpha of 0.1434, we suggest you to validate Biomarin Pharmaceutical's prevailing market performance to make sure the company can sustain itself at a future point.

Biomarin Pharmaceutical Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Biomarin Pharmaceutical middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Biomarin Pharmaceutical. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Biomarin Pharmaceutical Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomarin Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomarin Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomarin Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bienaime Jean Jacques over three months ago via Macroaxis 
Biomarin Pharmaceuticals exotic insider transaction detected
Jeff Ajer over three months ago via Macroaxis 
Sale by Jeff Ajer of 3000 shares of Biomarin Pharmaceuticals
Guyer Charles Greg over three months ago via Macroaxis 
Sale by Guyer Charles Greg of 6205 shares of Biomarin Pharmaceuticals
Brian Mueller over three months ago via Macroaxis 
Exercise or conversion by Brian Mueller of 3500 shares of Biomarin Pharmaceuticals subject to Rule 16b-3
Brian Mueller over three months ago via Macroaxis 
Sale by Brian Mueller of 7337 shares of Biomarin Pharmaceuticals
Davis George Eric over three months ago via Macroaxis 
Sale by Davis George Eric of 7398 shares of Biomarin Pharmaceuticals
Brian Mueller over three months ago via Macroaxis 
Payment of 576 shares by Brian Mueller of Biomarin Pharmaceuticals subject to Rule 16b-3
Jeff Ajer over three months ago via Macroaxis 
Payment of 7021 shares by Jeff Ajer of Biomarin Pharmaceuticals subject to Rule 16b-3
Jeff Ajer over six months ago via Macroaxis 
Sale by Jeff Ajer of 1308 shares of Biomarin Pharmaceuticals
Robert Hombach over six months ago via Macroaxis 
Acquisition by Robert Hombach of 4980 shares of Biomarin Pharmaceuticals subject to Rule 16b-3
Henry Fuchs over six months ago via Macroaxis 
Acquisition by Henry Fuchs of 35830 shares of Biomarin Pharmaceuticals subject to Rule 16b-3
Bienaime Jean Jacques over six months ago via Macroaxis 
Exercise or conversion by Bienaime Jean Jacques of 5000 shares of Biomarin Pharmaceuticals subject to Rule 16b-3

Biomarin Pharmaceutical Technical and Predictive Indicators

Biomarin Pharmaceutical Forecast Models

Biomarin Pharmaceutical time-series forecasting models is one of many Biomarin Pharmaceutical's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biomarin Pharmaceutical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Biomarin Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biomarin Pharmaceutical prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biomarin shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Biomarin Pharmaceutical. By using and applying Biomarin Stock analysis, traders can create a robust methodology for identifying Biomarin entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(4.46) (4.81) 
EBITDA Margin 2.03  2.19 
Gross Margin 74.52  85.49 
Profit Margin(3.47) (3.74) 

Current Biomarin Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biomarin analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biomarin analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
112.57Buy14Odds
Biomarin Pharmaceutical current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biomarin analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biomarin stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biomarin Pharmaceutical, talking to its executives and customers, or listening to Biomarin conference calls.
Biomarin Analyst Advice Details

Biomarin Stock Analysis Indicators

Biomarin Pharmaceutical stock analysis indicators help investors evaluate how Biomarin Pharmaceutical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biomarin Pharmaceutical shares will generate the highest return on investment. By understating and applying Biomarin Pharmaceutical stock analysis, traders can identify Biomarin Pharmaceutical position entry and exit signals to maximize returns.
Begin Period Cash Flow649158000.00
Logo U R LimglogosUSBMRN.png
Common Stock Shares Outstanding191678000.00
Total Stockholder Equity4270740000.00
DescriptionBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include
Total Cashflows From Investing Activities-366313000.00
Tax Provision-11270000.00
Quarterly Earnings Growth Y O Y1.133
Property Plant And Equipment Net1035461000.00
Retained Earnings-925689000.00
Cash And Short Term Investments1013875000.00
Retained Earnings Total Equity-925689000.00
Cash587276000.00
CodeBMRN
Accounts Payable193003000.00
Net Debt502265000.00
50 Day M A87.5072
Total Current Liabilities539822000.00
Currency CodeUSD
Other Operating Expenses1920608000.00
Non Current Assets Total3728940000.00
Forward Price Earnings27.933
Common Stock Total Equity184000.00
Non Currrent Assets Other151760000.00
Continue to Trending Equities. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for analysis

When running Biomarin Pharmaceutical price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
1.13
Market Capitalization
18.8 B
Quarterly Revenue Growth YOY
0.24
Return On Assets
6.0E-4
Return On Equity
0.019
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine Biomarin Pharmaceutical value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.